Solid Tumours Clinical Trial
Official title:
An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer
The purpose of this study is to explore the potential dose response relationship between the pharmacokinetics of GSK2141795 and [18F] FDG PET pharmacodynamic markers of glucose metabolism in tumor tissue. Three to six subjects will be enrolled in each cohort and dosed with repeat escalating doses of GSK2141795. [18F] FDG PET imaging and optional tumor biopsies will be done prior to initiation of dosing and sequentially at select time points during the first five weeks of dosing. The maximal dose of a given schedule evaluated in this study will not exceed the maximal tolerated dose established in the first-time-in-human trial PCS112689 for the same schedule.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03315091 -
Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours
|
Phase 1 | |
| Completed |
NCT01921140 -
To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours
|
Phase 1 | |
| Completed |
NCT00732420 -
Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03572192 -
Tissue Collection Framework To Improve Outcomes In Solid Tumours
|
||
| Completed |
NCT02360345 -
Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly
|
Phase 1 | |
| Completed |
NCT02264418 -
Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours
|
Phase 1 | |
| Completed |
NCT02093351 -
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
|
Phase 1 | |
| Completed |
NCT01956669 -
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT02215850 -
Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours
|
Phase 1 | |
| Recruiting |
NCT02263950 -
A Phase 1/2a Study of LON002 in Subjects With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
| Completed |
NCT01931761 -
Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers
|
Phase 1 | |
| Completed |
NCT01900028 -
To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours
|
Phase 1 | |
| Completed |
NCT00136578 -
Ispinesib In Combination With Carboplatin In Patients With Solid Tumors
|
Phase 1 | |
| Completed |
NCT01184274 -
A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia
|
Phase 1 | |
| Withdrawn |
NCT03266159 -
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT01894256 -
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function
|
Phase 1 | |
| Completed |
NCT01974349 -
To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
|
Phase 1 | |
| Completed |
NCT02923947 -
Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment
|
Phase 1 | |
| Completed |
NCT02056392 -
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
|
Phase 1 | |
| Completed |
NCT02063204 -
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects
|
Phase 1 |